N-[(benzyloxy)carbonyl]-L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide | 512783-80-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(benzyloxy)carbonyl]-L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide
• 英文别名: N-benzyloxycarbonyl-L-glutamic acid γ-t-butyl ester α-(3-trifluoromethyl)benzylamide
• CAS: 512783-80-1
• 化学式: C₂₅H₂₉F₃N₂O₅
• 分子量: 494.511
• InChiKey: LDHHIKUBCAWGAM-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.74
• 重原子数：
  35.0
• 可旋转键数：
  9.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  93.73
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-[(benzyloxy)carbonyl]-L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 以100%的产率得到L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide
  参考文献：
  名称：

  Azetidinones as vasopressin V1a antagonists

  摘要：

  The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor. Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with K-i values < 1 nM and brain levels after oral dosing similar to 100-fold higher than receptor affinities.[GRAPHICS](c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.031
• 作为产物：
  描述：

  3-(三氟甲基)苯甲胺 、 (4S)-5-[(2,5-二氧代-1-吡咯烷基)氧基]-5-氧代-4-[[(苯基甲氧基)羰基]氨基]戊酸叔丁酯 以 四氢呋喃 为溶剂， 以98%的产率得到N-[(benzyloxy)carbonyl]-L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide
  参考文献：
  名称：

  Azetidinones as vasopressin V1a antagonists

  摘要：

  The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor. Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with K-i values < 1 nM and brain levels after oral dosing similar to 100-fold higher than receptor affinities.[GRAPHICS](c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.031